Salix snags two new drugs in $300M Oceana buyout

Salix is snapping up Oceana Therapeutics for $300 million. Oceana has a pair of drugs on the market: Deflux, which is used to treat vesicoureteral reflux, a bladder problem known to trigger severe kidney infections and kidney damage in kids, and Solesta, a "tissue bulking agent" which can be used to treat incontinence. Story